Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.80 Analyst target: $2.50 Upside: 212.46%
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing a promising pipeline of allogeneic immunotherapies aimed at enhancing treatment outcomes for cancer patients and those with severe medical conditions, while reducing associated complications. With a strong leadership team and strategic partnerships, Celularity is positioned to become a significant force in the dynamic advanced therapeutics sector, addressing critical unmet medical needs and driving advancements in patient care.
See the full interactive analysis & chart →Informational only — not investment advice.